Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

被引:289
作者
Fekety, R
McFarland, LV
Surawicz, CM
Greenberg, RN
Elmer, GW
Mulligan, ME
机构
[1] UNIV WASHINGTON, DEPT MED CHEM, SCH PHARM, SEATTLE, WA 98195 USA
[2] UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV INFECT DIS, ANN ARBOR, MI 48109 USA
[3] UNIV WASHINGTON, SCH MED, DEPT MED, DIV GASTROENTEROL, SEATTLE, WA 98195 USA
[4] BIOCODEX INC, SEATTLE, WA USA
[5] UNIV KENTUCKY, DEPT MED, LEXINGTON, KY 40506 USA
[6] VET AFFAIRS MED CTR, DEPT INFECT DIS, LONG BEACH, CA USA
[7] UNIV CALIF IRVINE, IRVINE, CA 92717 USA
关键词
D O I
10.1093/clinids/24.3.324
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Recurrent Clostridium difficile diarrhea (RCDD) occurs in 20% of patients after they have received standard antibiotic treatment with vancomycin or metronidazole, but the reasons for the recurrences are largely unknown, Patients receiving vancomycin or metronidanole for active C, difficile diarrhea (CDD) were referred to our study centers for treatment and a 2-month follow-up as part of a randomized placebo-controlled trial. Sixty patients had RCDD (median number of episodes, 3.0; range, 2-9 episodes) and 64 were having their first episode of CDD. Patients with RCDD had more-severe abdominal pain and were more likely to have fever but initially responded well to antibiotic therapy, Data on sequential episodes showed no progression in disease severity, Five factors were associated with a higher risk of RCDD: the number of previous CDD episodes, onset of the initial disease in the spring, exposure to additional antibiotics for treatment of other infections, infection with immunoblot type 1 or 2 strains of C. difficile, and female gender, These factors may help to identify patients who are more likely to develop RCDD and require careful medical supervision.
引用
收藏
页码:324 / 333
页数:10
相关论文
共 48 条
[1]
BARTLETT JG, 1980, GASTROENTEROLOGY, V78, P431
[2]
CLOSTRIDIUM-DIFFICILE - HISTORY OF ITS ROLE AS AN ENTERIC PATHOGEN AND THE CURRENT STATE OF KNOWLEDGE ABOUT THE ORGANISM [J].
BARTLETT, JG .
CLINICAL INFECTIOUS DISEASES, 1994, 18 :S265-S272
[3]
ISOLATION OF CLOSTRIDIUM-DIFFICILE AT A UNIVERSITY HOSPITAL - A 2-YEAR STUDY [J].
BOWEN, KE ;
MCFARLAND, LV ;
GREENBERG, RN ;
RAMSEY, MM ;
RECORD, KE ;
SVENSON, J .
CLINICAL INFECTIOUS DISEASES, 1995, 20 :S261-S262
[4]
BRESLOW NE, 1987, IARC SCI PUBL, V82, P83
[5]
BROWN E, 1990, INFECT CONT HOSP EP, V11, P283
[6]
ACQUISITION OF CLOSTRIDIUM-DIFFICILE BY HOSPITALIZED-PATIENTS - EVIDENCE FOR COLONIZED NEW ADMISSIONS AS A SOURCE OF INFECTION [J].
CLABOTS, CR ;
JOHNSON, S ;
OLSON, MM ;
PETERSON, LR ;
GERDING, DN .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (03) :561-567
[7]
ORAL BACITRACIN VS VANCOMYCIN THERAPY FOR CLOSTRIDIUM-DIFFICILE - INDUCED DIARRHEA - A RANDOMIZED DOUBLE-BLIND TRIAL [J].
DUDLEY, MN ;
MCLAUGHLIN, JC ;
CARRINGTON, G ;
FRICK, J ;
NIGHTINGALE, CH ;
QUINTILIANI, R .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (06) :1101-1104
[8]
Biotherapeutic agents - A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [J].
Elmer, GW ;
Surawicz, CM ;
McFarland, LV .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (11) :870-876
[9]
DIAGNOSIS AND TREATMENT OF CLOSTRIDIUM-DIFFICILE COLITIS [J].
FEKETY, R ;
SHAH, AB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (01) :71-75
[10]
EPIDEMIOLOGY OF ANTIBIOTIC-ASSOCIATED COLITIS - ISOLATION OF CLOSTRIDIUM DIFFICLE FROM THE HOSPITAL ENVIRONMENT [J].
FEKETY, R ;
KIM, KH ;
BROWN, D ;
BATTS, DH ;
CUDMORE, M ;
SILVA, J .
AMERICAN JOURNAL OF MEDICINE, 1981, 70 (04) :906-908